For the Inventor, By the Inventor

Enter assignee name

Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.

USPTO Granted Patents = 72

% Expired Patents = 9.7

CIPO Patents = 4

EPO Patents = 13

Forward Citations = 1,881

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

David M Goldenberg (69 out of 393 patents)

Chien-Hsing Chang (66 out of 140 patents)

Edmund A Rossi (52 out of 77 patents)

4. William John McBride (22 out of 85 patents)

5. Diane Rossi (11 out of 13 patents)

6. Chien Hsing Chang (4 out of 8 patents)

7. Hans J Hansen (3 out of 191 patents)

8. Rongxiu Li (3 out of 3 patents)

9. Donglin Liu (2 out of 5 patents)

10. Serengulam V Govindan (1 out of 112 patents)

11. Fernando Jose Rebelo Do Couto (1 out of 31 patents)

12. Roberto L Ceriani (1 out of 17 patents)

13. Jerry A Peterson (1 out of 1 patent)

14. William J Mcbride (0 patent)

15. Chien-Hsing Ken Chang (0 patent)

Core Competencies:

Bispecific Antibodies

Cytokines

DNL Technology

Immunoconjugates

Checkpoint Inhibitors

Combination Therapy

Immunotoxins

Trop-2

Anti-TNF-alpha

HIV Therapy

Multivalent Complexes

Cancer Vaccines

72 patents: Sort by Forward Citations

1. 10662252 - Disease therapy by inducing immune response to Trop-2 expressing cells (2020-05-26),

2. 10385139 - Murine, chimeric, humanized or human anti-TNF-alpha antibodies (2019-08-20),

3. 10308688 - T-cell redirecting bispecific antibodies for treatment of disease (2019-06-04),

4. 10280220 - Immunoconjugates with an intracellularly-cleavable linkage (2019-05-07),

5. 10245321 - Combination therapy for inducing immune response to disease (2019-04-02),

6. 10239938 - T-cell redirecting bispecific antibodies for treatment of disease (2019-03-26),

7. 10183992 - T-cell redirecting bispecific antibodies for treatment of disease (2019-01-22),

8. 10131712 - Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors (2018-11-20),

9. 10111954 - Combination therapy for inducing immune response to disease (2018-10-30),

10. 10022427 - Interferon lambda-antibody complexes (2018-07-17),

11. 9932413 - Murine, chimeric, humanized or human anti-IL-6 antibodies (2018-04-03),

12. 9931413 - Tetrameric cytokines with improved biological activity (2018-04-03),

13. 9879088 - Disease therapy by inducing immune response to Trop-2 expressing cells (2018-01-30),

14. 9872920 - PEGylation by the dock and lock (DNL) technique (2018-01-23),

15. 9862770 - Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors (2018-01-09),

Company Overview

Ibc Pharmaceuticals, Inc., based in Morris Plains, NJ, specializes in the development of innovative immunotherapy solutions. The company focuses on advanced therapeutic modalities, including bispecific antibodies, cytokines, and immunoconjugates, aimed at enhancing the efficacy of cancer treatments. Ibc Pharmaceuticals is dedicated to pioneering combination therapies and checkpoint inhibitors, leveraging its proprietary DNL technology and expertise in immunotoxins to address unmet medical needs in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

72 Patents

#3 in Morris Plains, NJ

#220 in New Jersey

#5,108 in US

#10,396 in the World

Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.

Forward Citations = 1,881

13 inventors:

David M Goldenberg (69 out of 393 patents)

Chien-Hsing Chang (66 out of 140 patents)

Edmund A Rossi (52 out of 77 patents)

4. William John McBride (22 out of 85 patents)

5. Diane Rossi (11 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ibc Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/ibc-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…